EVALUATION OF THE EFFECTS OF SGLT2 INHIBITORS ON HEART FAILURE AND LEFT VENTRICULAR DIASTOLIC FUNCTION PARAMETERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Ключевые слова:
SGLT2 inhibitors, heart failure, left ventricular diastolic function, diabetic cardiomyopathyАннотация
This article investigates the effects of SGLT2 inhibitors on heart failure and left ventricular diastolic function in patients with type 2 diabetes mellitus. The study analyzes the pathophysiological relationship between diabetes and cardiovascular complications, focusing on diabetic cardiomyopathy and diastolic dysfunction. The impact of SGLT2 inhibitors on cardiac remodeling, myocardial relaxation, and heart failure symptoms was evaluated using clinical and echocardiographic parameters. The findings indicate that SGLT2 inhibitors improve cardiac function, reduce the progression of heart failure, and decrease cardiovascular risk. The results confirm the cardioprotective potential of these agents and support their use in the comprehensive management of patients with type 2 diabetes mellitus
##plugins.themes.default.displayStats.downloads##
Библиографические ссылки
1. Abdullayev A.A. Modern Aspects of Cardiovascular Complications in Diabetes Mellitus // New Day in Medicine. – Tashkent, 2023. – No. 4. – P. 52–58.
2. Karimov Sh.T., Ergashev N.N. Clinical Features of Heart Failure Development in Patients with Type 2 Diabetes Mellitus // Uzbek Journal of Therapy. – Tashkent, 2024. – No. 2. – P. 34–41.
3. Ismoilov B.B. Diabetic Cardiomyopathy and Its Modern Diagnostic Approaches // Theoretical and Clinical Medicine. – Tashkent, 2023. – No. 3. – P. 61–68.
4. American Diabetes Association Standards of Care 2025. Standards of Medical Care in Diabetes—2025 // Diabetes Care. – 2025. – Vol. 48, Suppl. 1. – P. 1–350.
5. Zinman Bernard, Wanner Christoph et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes // The New England Journal of Medicine. – 2015. – Vol. 373, No. 22. – P. 2117–2128.
6. McMurray John J.V., Solomon Scott D. et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction // The New England Journal of Medicine. – 2019. – Vol. 381, No. 21. – P. 1995–2008.
7. Packer Milton, Anker Stefan D. et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure // The New England Journal of Medicine. – 2020. – Vol. 383, No. 15. – P. 1413–1424.
8. Solomon Scott D., McMurray John J.V. et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction // The New England Journal of Medicine. – 2022. – Vol. 387, No. 12. – P. 1089–1098.
9. Braunwald Eugene. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. – 12th ed. – Philadelphia: Elsevier, 2022. – 2048 p.
10. Borlaug Barry A.. Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction // Nature Reviews Cardiology. – 2020. – Vol. 17, No. 9. – P. 559–573
